2024-03-28T14:28:53Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00024846
2023-01-16T04:15:25Z
499:500:501
Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells
Masahiro, Shibata
Mitsuro, Kanda
Haruyoshi, Tanaka
Shinichi, Umeda
Takashi, Miwa
Dai, Shimizu
Masamichi, Hayashi
Takahiro, Inaishi
Noriyuki, Miyajima
Yayoi, Adachi
Yuko, Takano
Kenichi, Nakanishi
Dai, Takeuchi
Sumiyo, Noda
Yasuhiro, Kodera
Toyone, Kikumori
open access
Breast cancer (BC) is the most common malignant tumor among women worldwide. Development of novel molecular targets is important to improve prognosis of BC patients. Derlin 3 (DERL3) gene is a member of derlin family, and its coding protein is critical to the endoplasmic reticulum-associated degradation mechanism. However, its oncological role in breast cancer remains unclear. This study evaluated DERL3 expression and function in BC. We analyzed DERL3 mRNA in 13 BC and two non-cancerous cell lines, and explored effects of DERL3 knockdown on BC proliferation, invasion and migration. We also evaluated correlation of DERL3 mRNA expression levels with clinicopathological factors and prognosis in 167 BC patients. DERL3 mRNA expression was detected in five (38%) BC cell lines. Inhibiting DERL3 expression significantly decreased proliferation and invasion in BC cells. Specimens from patients with lymph node metastasis had higher DERL3 mRNA expression than those without (P=0.030). Patients in the highest quartile for DERL3 mRNA expression (n=42) were more likely to experience shorter overall survival than other patients (P=0.032). These findings indicate that DERL3 promotes malignant phenotype in BC cells. DERL3 may serve as a potential prognostic marker and therapeutic target for BC.
Spandidos Publications
2017-07-10
eng
journal article
AM
http://hdl.handle.net/2237/27066
https://nagoya.repo.nii.ac.jp/records/24846
https://doi.org/10.3892/or.2017.5800
1021-335X
Oncology Reports
38
3
1760
1766
https://nagoya.repo.nii.ac.jp/record/24846/files/DERL3-BCC_Oncol_Rep_2017.pdf
application/pdf
555.3 kB
2018-01-10